United States newsroom

Babs is sharing her family’s history with progressive retinal disease GA, the advanced form of dry age-related macular degeneration (AMD), is a serious condition that may lead to irreversible...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical...

Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy...

Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the invaluable expertise provided by Astellas to advance their...

Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise to further their research Award helps biotech start-ups accelerate early drug...

FOR IMMEDIATE RELEASE – NORTHBROOK, IL, Dec. 23, 2024 – Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") is voluntarily recalling one lot of PROGRAF® 0.5mg...

"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives. NORTHBROOK, Ill., Dec. 5, 2024 /PRNewswire/ -- Astellas Pharma...

SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare...

ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today...

The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners

- Collaboration to focus on gene therapy research for the treatment of ultra-rare disease NORTHBROOK, Ill., June 20, 2024 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today the...

Community-driven collaboration aims to raise awareness of the value PAOs offer patients and their caregivers NORTHBROOK, Ill., June 10, 2024 /PRNewswire/ -- Astellas is proud to announce that it...

- 154,000 square-foot lab and office facility creates a central location for Astellas' West Coast cell and gene therapy research and business development operations TOKYO and SAN FRANCISCO, May 8,...

Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today...

Designation follows December 2023 FDA approval for the treatment of these serious, potentially life-threatening fungal infections in children CRESEMBA receives seven years and six months of US...

NORTHBROOK, Ill., Feb. 22, 2024 /PRNewswire/ -- Today, Astellas Pharma Inc. Chief Commercial Officer Claus Zieler has named Michael Petroutsas as Head, United States Commercial, leading the...

Astellas is returning to the Super Bowl to help educate game viewers about VEOZAH and vasomotor symptoms (VMS), the most commonly reported menopause symptoms1 The "Fewer Hot Flashes, More Not Flashes"

Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco, CA, along with the invaluable expertise provided by Astellas to advance...

CRESEMBA is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections Approval based on results of two...

GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States1,2 Eric and his mother, Jamey, are...

If approved, CRESEMBA will offer a new treatment option for pediatric patients facing certain invasive fungal infections NORTHBROOK, Ill., Aug. 10, 2023 /PRNewswire/ -- Astellas Pharma US, Inc....

Both Companies win a year of access to a prestigious life-science incubator in San Francisco, CA and to Astellas expertise to further their research Award helps biotech start-ups accelerate early...

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 19, 2022 /PRNewswire/ --...

- Winner developed app to empower cancer patients after experience as a cancer caregiver - NORTHBROOK, Ill., Aug. 8, 2022 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced the...